Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESA-E: LSD Microdosing for Mood
NCT03934710Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Apr 2019
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lysergide in major depressive disorder (MDD) (3 arms), sponsored by University of Chicago. Primary endpoint: Depression Anxiety Stress Scales-21 at 2 weeks. Started Apr 2019; status: completed.
02
Drugs
Lysergide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03934710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934710.